Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

被引：0

作者：

W Chua

D Goldstein

C K Lee

H Dhillon

M Michael

P Mitchell

S J Clarke

B Iacopetta

机构：

[1] Sydney Cancer Centre,Department of Medical Oncology

[2] Concord Repatriation General Hospital,Department of Medical Oncology

[3] Prince of Wales Hospital,Division of Haematology and Medical Oncology

[4] NHMRC Clinical Trials Centre,Department of Medical Oncology

[5] Centre of Medical Psychology and Evidence-based Decision-Making,undefined

[6] University of Sydney,undefined

[7] Peter MacCallum Cancer Centre,undefined

[8] Austin Hospital,undefined

[9] School of Surgery,undefined

[10] University of Western Australia,undefined

来源：

British Journal of Cancer | 2009年 / 101卷

关键词：

colorectal cancer; metastatic; chemotherapy; predictive factors;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：998 / 1004

页数：6

共 50 条

[41] Change in systemic inflammation markers and CEA levels as predictive marker for chemotherapy response and prognosis in metastatic colorectal cancer
Kim, In-Ho
Lee, In Hee
Lee, Ji Eun
Oh, Seong Taek
Kim, Jun Ki
Lee, Myung Ah
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[42] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
Vaidyanathan, Gayatri
Groman, Adrienne
Wilding, Gregory
Fakih, Marwan G.
ONCOLOGY, 2010, 79 (1-2) : 67 - 71
[43] Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Astrid Lièvre
Emmanuelle Samalin
Emmanuel Mitry
Eric Assenat
Christine Boyer-Gestin
Céline Lepère
Jean-Baptiste Bachet
Fabienne Portales
Jean-Nicolas Vaillant
Marc Ychou
Philippe Rougier
BMC Cancer, 9
[44] Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
Shitara, K.
Matsuo, K.
Takahari, D.
Yokota, T.
Ura, T.
Muro, K.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[45] Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
Cybulska-Stopa, Bozena
Lugowska, Iwona
Wisniowski, Rafal
Domagala-Haduch, Malgorzata
Rajczykowski, Marcin
Piejko, Karolina
Bar-Letkiewicz, Ilona
Suwinski, Rafal
Regulski, Krzysztof
Mackiewicz, Jacek
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2020, 24 (01): : 34 - 41
[46] Oxaliplatin,Fluorouracil and Leucovorin (FOLFOX) as First-line Chemotherapy for Metastatic or Recurrent Colorectal Cancer Patients
Bing Han Ruihua Xu Yanxia Shi Huiyan Luo Xiaojuan Xiang Yuhong Li Li Zhang Tongyu Lin Youjian HeDepartment of Medical Oncology
Chinese Journal of Clinical Oncology, 2007, (06) : 397 - 400
[47] Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
Shitara, Kohei
Matsuo, Keitaro
Takahari, Daisuke
Yokota, Tomoya
Inaba, Yoshitaka
Yamaura, Hidekazu
Sato, Yozo
Najima, Mina
Ura, Takashi
Muro, Kei
EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) : 1757 - 1763
[48] Determination of genomic profile to predict clinical response to FOLFOX plus bevacizumab in metastatic colorectal cancer
George, T. J.
Liu, H.
Duckworth, L. V.
Sullivan, J. E.
Dong, J.
Liu, C.
Dang, L. H.
Slentz-Kesler, K.
Allegra, C. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[49] Molecular markers of chemotherapy in advanced colorectal cancer: Back to square one
Sobrero, Alberto
EUROPEAN JOURNAL OF CANCER, 2009, 45 (11) : 1902 - 1903
[50] EFFICACY OF FOLFOX4 REJIMEN FOR METASTATIC COLORECTAL CANCER
Ogura, Mariko
Matsusaka, Satoshi
Kuboki, Yasutoshi
Takashi, Ichimura
Watanabe, Toshiyasu
Takagi, Kouichi
Nozaki, Akira
Ozaka, Masato
Shinozaki, Eiji
Suenaga, Mitsukuni
Chin, Keisyou
Mizunuma, Nobuyuki
Hatake, Kiyohiko
ANNALS OF ONCOLOGY, 2010, 21 : 30 - 30

← 1 2 3 4 5 →